Quinidine
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1950
- First approval year
- 1950
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Quinidine
- Molecular weight
- 324.42
- Structure (SMILES)
- C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12
- .beta.-quinidine
- (+)-QUINIDINE
- (8r,9s)-quinidine
- 8r 9s quinidine
- beta quinidine
- cinchonan 9 ol 6 methoxy 9s
- CINCHONAN-9-OL, 6'-METHOXY-, (9S)-
- conquinine
- Conquinine
- kinidin
- Kinidin
- pitayine
- Pitayine
- quinidine
- Quinidine
- QUINIDINE [HSDB]
- QUINIDINE [MART.]
- QUINIDINE [MI]
- QUINIDINE [VANDF]
- Quinidine [WHO-DD]
- quinidine hsdb
- quinidine mart
- quinidine mi
- quinidine vandf
- quinidine who dd
And 10 more, listed on the interactive page.
- CAS registry numbers
- 56-54-2
- ChEMBL ID
- CHEMBL1294
- InChIKey
- LOUPRKONTZGTKE-LHHVKLHASA-N
- PubChem compound IDs
- 441074
- FDA ingredient codes (UNII)
- ITX08688JL
- C01BA01
- C01BA51
- C01BA71
Sources for recorded values
- 9068
- 35220
- Applicant
- LILLY
- Approval date
- 12 Jul 1950
- Application number
- NDA007529
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- Pharmacology name
- quinidine
- Type
- Natural product
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Parenteral
- Action
- Antagonist
- Action type
- Antagonist
- Target
- KNa1.1
- Gene symbol
- KCNT1
- Protein identifier
- Q5JUK3
- Action
- Channel blocker
- Action type
- Channel blocker
- Target
- VRAC
- Gene symbol
- VRAC
- Action
- Channel blocker
- Action type
- Channel blocker
- Target
- KCa5.1
- Gene symbol
- KCNU1
- Protein identifier
- A8MYU2
- Action
- Channel blocker
- Action type
- Channel blocker
- Target
- Kv10.1
- Gene symbol
- KCNH1
- Protein identifier
- O95259
- Median affinity
- 5.8
- Affinity units
- pIC50
- Action
- Channel blocker
- Action type
- Channel blocker
- Target
- K2P5.1
- Gene symbol
- KCNK5
- Protein identifier
- O95279
- Action
- Channel blocker
- Action type
- Channel blocker
- Target
- Kv1.5
- Gene symbol
- KCNA5
- Protein identifier
- P22460
- Median affinity
- 5.2
- Affinity units
- pKd
- Action
- Channel blocker
- Action type
- Channel blocker
- Target
- Kv1.7
- Gene symbol
- KCNA7
- Protein identifier
- Q96RP8
- Median affinity
- 4.8
- Affinity units
- pKd
- Action
- Channel blocker
- Action type
- Channel blocker
- Target
- K2P16.1
- Gene symbol
- KCNK16
- Protein identifier
- Q96T55
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- Plasma membrane monoamine transporter
- Gene symbol
- SLC29A4
- Protein identifier
- Q7RTT9
- Median affinity
- 4.6
- Affinity units
- pKi
- Action
- Pore blocker
- Action type
- PORE_BLOCKER
- Target
- Kv10.2
- Gene symbol
- KCNH5
- Protein identifier
- Q8NCM2
- Median affinity
- 3.8
- Affinity units
- pIC50
Open Targets mechanisms
- Mechanism
- Sodium channel alpha subunit blocker
- Action type
- Blocker
- Target
- Sodium channel alpha subunit
- Action type
- Blocker
- Gene symbol
- KCNH1
- Protein identifier
- O95259
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Blocker
- Gene symbol
- KCNA5
- Protein identifier
- P22460
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Blocker
- Gene symbol
- SCN1A|SCN2A|SCN3A
- Protein identifier
- P35498|Q99250|Q9NY46
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Blocker
- Gene symbol
- SCN5A
- Protein identifier
- Q14524
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Blocker
- Gene symbol
- KCNA7
- Protein identifier
- Q96RP8
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Inhibitor
- Gene symbol
- CYP2D6
- Protein identifier
- P10635
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Inhibitor
- Gene symbol
- SLC29A4
- Protein identifier
- Q7RTT9
- Organism
- Homo sapiens
- Target development level
- Biological evidence
- Condition
- Atrial Fibrillation
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000275
- Subject identifier
- D001281
- Condition
- Myocardial Infarction
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000612
- Subject identifier
- D009203
- Condition
- Hepatitis B, Chronic
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004197
- Subject identifier
- D019694
- Condition
- Arrhythmias, Cardiac
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004269
- Subject identifier
- D001145
- Condition
- Death, Sudden, Cardiac
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004278
- Subject identifier
- D016757
- Condition
- Ventricular Fibrillation
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004287
- Subject identifier
- D014693
- Condition
- Non-alcoholic Fatty Liver Disease
- Highest recorded phase
- 1
- Condition identifier
- EFO:1001249
- Subject identifier
- D065626
- Condition
- Respiratory Syncytial Virus Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:1001413
- Subject identifier
- D018357
- Condition
- Constipation
- Highest recorded phase
- 1
- Condition identifier
- HP:0002019
- Subject identifier
- D003248
- Condition
- Depressive Disorder, Major
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002009
- Subject identifier
- D003865
- Condition
- Depressive Disorder
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002050
- Subject identifier
- D003866
- Condition
- Amyotrophic Lateral Sclerosis
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0004976
- Subject identifier
- D000690
- Condition
- Migraine Disorders
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005277
- Subject identifier
- D008881
- Condition
- Multiple Sclerosis
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005301
- Subject identifier
- D009103
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0004197
- Highest recorded phase
- 1
- Condition identifier
- EFO_0004269
- Condition identifier
- EFO_0004269
- Highest recorded phase
- 4
- Condition identifier
- EFO_0005762
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000783
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001249
- Highest recorded phase
- 1
- Condition identifier
- HP_0000713
- Highest recorded phase
- 2
- Condition identifier
- HP_0000737
- Highest recorded phase
- 3
- Condition identifier
- HP_0001699
- Highest recorded phase
- 3
- Condition identifier
- HP_0002019
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0000190
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002009
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002009
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002050
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004975
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004976
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004981
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005180
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005277
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005301
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005301
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005477
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006626
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008222
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0100234
- Highest recorded phase
- 2
Open Targets warnings
- Warning
- Black Box Warning
- Effect
- cardiotoxicity
- Country
- United States
- Event
- atrioventricular block
- Reports
- 7
- Reporting signal score
- 25.0005
- Event
- blood ketone body decreased
- Reports
- 1
- Reporting signal score
- 7.45954
- Event
- brugada syndrome
- Reports
- 3
- Reporting signal score
- 13.828
- Event
- cerebral malaria
- Reports
- 1
- Reporting signal score
- 7.3542
- Event
- cyp2d6 polymorphism
- Reports
- 1
- Reporting signal score
- 7.09191
- Event
- drug hypersensitivity
- Reports
- 18
- Reporting signal score
- 24.7978
- Event
- drug-genetic interaction
- Reports
- 1
- Reporting signal score
- 7.45954
- Event
- electrocardiogram qrs complex prolonged
- Reports
- 4
- Reporting signal score
- 13.6101
- Event
- electrocardiogram qt prolonged
- Reports
- 31
- Reporting signal score
- 109.477
- Event
- haemoglobinuria
- Reports
- 2
- Reporting signal score
- 9.3966
- Event
- long qt syndrome
- Reports
- 3
- Reporting signal score
- 11.2651
- Event
- multiple-drug resistance
- Reports
- 4
- Reporting signal score
- 16.3343
- Event
- ototoxicity
- Reports
- 2
- Reporting signal score
- 7.08267
- Event
- seizure
- Reports
- 6
- Reporting signal score
- 7.62338
- Event
- status epilepticus
- Reports
- 4
- Reporting signal score
- 10.2399
- Event
- treatment failure
- Reports
- 8
- Reporting signal score
- 13.4192
- Event
- ventricular tachycardia
- Reports
- 4
- Reporting signal score
- 8.73092
- NCT00000464
- NCT00000556
- NCT00789165
- NCT00021697
- NCT03883581
- NCT00050232
- NCT01460381
- NCT01882829
- NCT01533155
- NCT02153502
- NCT02176018
- NCT03610945
- NCT03755778
- NCT04783753
- NCT05594602
- Dose
- 1 capsule, then 1 capsule every 12 hours
- Route
- Oral
- How often
- Once daily for 7 days, then twice daily after 7 days
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 1
- Polar surface area
- 45.59
- Calculated partition coefficient (ALogP)
- 3.17
- Calculated partition coefficient (XLogP)
- 2.9
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 4
- Heavy atoms
- 24
- Molecular formula
- C20H24N2O2
- Monoisotopic mass
- 324.183778013
- Natural product
- Yes
- Recorded assays
- 4,147
- Active assays
- 224
- Confirmatory
- Other
- Screening
- Summary
- Adrenergic alpha-Antagonists
- Anti-Arrhythmia Agents
- Antimalarials
- Enzyme Inhibitors
- Muscarinic Antagonists
- Voltage-Gated Sodium Channel Blockers
- Cytochrome P-450 CYP2D6 Inhibitors
These details could not be displayed.
Related records
Trials (24)
- A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
- A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants
- A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.
- A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers
- A Study of Imlunestrant (LY3484356) in Female Healthy Participants
- A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants
- A Study to Evaluate the Effect of Genotype on LY2216684
- A Study to Investigate the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants.
- A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine
- Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)
- Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)
- Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.
- Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers
- Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy Subjects
- Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects
- Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males
- Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM)
- Empiric Quinidine for Asymptomatic Brugada Syndrome
- Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease
- Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine
Approved for (1)
- Cardiac rhythm disease
In development for (15)
- Amyotrophic lateral sclerosis Phase 3
- Atrial fibrillation Phase 3
- Constipation disorder Phase 1
- COVID-19 Phase 1
- Depressive disorder Phase 2
- Diabetic neuropathy Phase 2
- Hepatitis B virus infection Phase 1
- Major depressive disorder Phase 2
- Metabolic dysfunction-associated steatohepatitis Phase 1
- Migraine disorder Phase 2
- Multiple sclerosis Phase 3
- Myocardial infarction Phase 3
- Respiratory syncytial virus infectious disease Phase 1
- Sudden cardiac arrest Phase 3
- Ventricular fibrillation Phase 3
Targets (10)
- SCN10A Sodium channel alpha subunit blocker
- SCN11A Sodium channel alpha subunit blocker
- SCN1A Sodium channel alpha subunit blocker
- SCN2A Sodium channel alpha subunit blocker
- SCN3A Sodium channel alpha subunit blocker
- SCN4A Sodium channel alpha subunit blocker
- SCN5A Sodium channel alpha subunit blocker
- SCN7A Sodium channel alpha subunit blocker
- SCN8A Sodium channel alpha subunit blocker
- SCN9A Sodium channel alpha subunit blocker